Company Encyclopedia
View More
name
Indaptus Therapeutics
INDP.US
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc.
1.912 T
INDP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pre-market hot trades in US stocks: Lianhe Sowell up 16.08% in pre-market; Indaptus Therapeutics up 8.07% in pre-market

    Lianhe Sowell pre-market up 16.08%; Indaptus Therapeutics pre-market up 8.07%; SMX Security Matters pre-market up 89.66%; HeartBeam pre-market up 35.53%; Aditxt pre-market up 24.21%

    Tracking Unusual Activity·
    US
    LHSW
    -4.91%
    US
    INDP
    -3.79%
    Tracking Unusual Activity·
    US
    LHSW
    -4.91%
    US
    INDP
    -3.79%

    Indaptus Therapeutics Q3 profit beats estimates

    Indaptus Therapeutics reported a Q3 2025 EPS of -$2.98, beating analyst expectations of -$4.17. The company raised $2.3 million to strengthen its balance sheet, while R&D expenses increased due to Phase 1 study costs. Indaptus expects its current cash to support operations into Q1 2026 and is evaluating financing options. Trial enrollment is paused pending further efficacy evaluations. The average analyst recommendation is "buy," with a 12-month price target of $25.00, significantly above its recent closing price of $2.72.

    Reuters·
    US
    INDP
    -3.79%
    Reuters·
    US
    INDP
    -3.79%

    Indaptus Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    INDP
    -3.79%
    LB filings·
    US
    INDP
    -3.79%

    Indaptus Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    INDP
    -3.79%
    LB filings·
    US
    INDP
    -3.79%

    Indaptus Therapeutics posts third quarter net loss of $2.98 per share

    Indaptus Therapeutics Inc. reported a net loss of $2.98 per share for Q3 2025, with R&D expenses of approximately $1.5 million, up from $1.4 million in Q3 2024. The company used $11.6 million in operating activities in the first nine months of 2025, compared to $8.9 million in 2024. Cash reserves totaled $5.8 million as of September 30, 2025, expected to last into Q1 2026. The company completed a Phase 1 trial cohort with promising results, with three out of six participants achieving stable disease.

    Reuters·
    US
    INDP
    -3.79%
    Reuters·
    US
    INDP
    -3.79%
    © 2025 Longbridge｜Disclaimer